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Coronary artery disease (CAD) is the largest killer of males and females in the United States. There is a need to develop
innovative diagnostic markers for this disease. MicroRNAs (miRNAs) are a class of noncoding RNAs that posttranscriptionally
regulate the expression of genes involved in important cellular processes, and we hypothesized that the miRNA expression proﬁle
would be altered in whole blood samples of patients with CAD. We performed a microarray analysis on RNA from the blood
of 5 male subjects with CAD and 5 healthy subjects (mean age 53 years). Subsequently, we performed qRT-PCR analysis of
miRNA expression in whole blood of another 10 patients with CAD and 15 healthy subjects. We identiﬁed 11 miRNAs that
were signiﬁcantly downregulated in CAD subjects (P<. 05). Furthermore, we found an association between ACEI/ARB use and
downregulation of several miRNAs that was independent of the presence of signiﬁcant CAD. In conclusion, we have identiﬁed a
distinct miRNA signature in whole blood that discriminates CAD patients from healthy subjects. Importantly, medication use may
signiﬁcantly alter miRNA expression. These ﬁndings may have signiﬁcant implications for identifying and managing individuals
that either have CAD or are at risk of developing the disease.
1.Introduction
Coronaryarterydisease(CAD)isamajorpublichealthprob-
lem worldwide and the single largest cause of mortality in
the United States, responsible for one of every six deaths
(AHA Heart Disease and Stroke Statistics, 2010). CAD is
caused by atherosclerosis, which is an inﬂammatory disease
that involves multiple cell types, including circulating cells
and cells in the vessel wall [1]. Despite advances in risk factor
management on an epidemiological level, many individuals
continue to succumb to CAD. Various blood markers
associated with increased risk for death and cardiovascular
endpoints have been identiﬁed, but currently very few have
beenshowntohaveadiagnosticimpactorimportantclinical
implications that would aﬀect patient management [2].
Therefore, there is a great need for innovative biomarkers
that can assess risk for CAD, assess activity of the atheroscle-
rotic process, and guide evaluation of therapy.
Several recent studies have suggested that circulating
microRNAscouldbeusefulasbiomarkersforvarioushuman
disease states, including cancer [3], acute myocardial infarc-
tion [4–7], heart failure, and chronic vascular disease [8,
9]. MicroRNAs (miRNAs) are a recently recognized class
of short (19–25nt), single-stranded, noncoding RNAs that
regulate an array of cellular functions through the degra-
dation and translational repression of mRNAs that contain
complementary sequences. More than 1000 human miRNAs
have been identiﬁed, and, in tissues, miRNAs regulate the
expression of genes involved in critical cellular processes,
including diﬀerentiation, growth, proliferation, and apopto-
sis [10]. Importantly, miRNAs are now regarded as rheostats
that ﬁne-tune expression of proteins involved in just about
every process in human cells [11].
miRNAs have been found in tissues, whole blood, serum,
plasma, and other body ﬂuids in a stable form that is pro-
tected from endogenous RNase activity [3, 12]. Although the2 Cardiology Research and Practice
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Figure 1: Volcano plot of all pairwise comparisons. Comparisons
of all small RNAs assessed in microarray analysis of RNA isolated
frombloodofpatientswithCAD(n = 5)orhealthyvolunteers(n =
5). The volcano plot displays the relationship between fold-change
and signiﬁcance between the two groups, using a scatter plot view.
The y-axis is the negative log10 of P values (a higher value indicates
greater signiﬁcance) and the x-axis is the diﬀerence in expression
betweentwoexperimentalgroupsasmeasuredinglog2space.Probes
identiﬁed as signiﬁcant are labeled on the plot (FDR t-test <0.05).
Subsequent to this analysis, miR-1308 has been removed from the
Sanger database because it is a fragment of a tRNA.
biological function of miRNA is yet to be fully understood,
tissue levels of speciﬁc miRNAs have been shown to correlate
with pathological development of diﬀerent diseases [13].
MiRNAs function as managers in gene regulatory networks,
and they are distinct from other biomarkers because they
have a pathogenic role in the disease process and are not
merely byproducts of the disease state. This feature of
miRNAs also enhances their attractiveness as therapeutic
targets. Thus, miRNA expression signatures in tissues and
blood have a potential role in the diagnosis, prognosis, and
assessment of therapy.
In this study, we sought to compare miRNA expression
in whole blood of patients with angiographically signiﬁcant
CAD to that of healthy aged-matched controls. We per-
formed an initial exploratory microarray analysis in 5 cases
and controls and then further examined the most highly
expressed miRNAs in an additional 15 cases and controls.
2.MaterialsandMethods
2.1. Study Population
2.1.1. CAD Subjects. Study participants were recruited as
part of the Emory Cardiology Biobank, consisting of 3492
consecutive patients enrolled prior to undergoing elective or
emergent cardiac catheterization across three Emory Health-
care sites, between 2003 and 2008. Patients aged 20–90 years
were interviewed to collect demographic characteristics,
medical history, and lifestyle habits. Risk factor prevalence
was determined by physician diagnosis and/or treatment for
hypertension, hyperlipidemia, and diabetes.
Coronary angiograms were evaluated independently by
two operators, who made visual estimation of luminal nar-
rowing in multiple segments based on a modiﬁed form of
the AHA/ACC classiﬁcation of the coronary tree. Using these
data, signiﬁcant CAD was deﬁned as at least one major
epicardial vessel with >50% stenosis, assessed by quantitative
coronary angiography. Additionally, we collected whole
blood samples from patients with ≥2 risk factors for CAD,
butdidnothaveangiographicallysigniﬁcantCAD.Thestudy
was approved by the Institutional Review Board at Emory
University, Atlanta, GA, USA. All subjects provided written
informed consent at the time of enrollment.
2.1.2. Healthy Controls. The healthy subject cohort was
a random sample of employees from Emory University who
were fully employed, productive people. These subjects were
aged 18 and older, not taking medications, and had not been
hospitalized for at least one year prior to participation. All
subjects provided written informed consent at the time of
enrollment.
2.2. RNA Isolation. Venous blood samples were drawn via
antecubial venipuncture into PAXgene Blood RNA Tubes
a n ds t o r e da t−20◦C within 24 hours before RNA extraction.
miRNA was isolated using the PreAnalytiX PAXgene miRNA
isolationkit(Qiagen)accordingtothemanufacturer’sproto-
col.
2.3. Microarray Analysis. miRNA microarray analysis was
performed by Asuragen, Inc., which uses the Aﬀymetrix
manufactured GeneChip miRNA arrays. Quality assess-
ment of the samples was done using TaqMan assays. The
microRNA targets were biotinylated using an Asuragen
developed direct labeling procedure. Once labeled, the
miRNA targets were hybridized overnight onto the microar-
rays following which the arrays were washed and stained
using Streptavidin-Phycoerythrin (SAPE). Arrays were pro-
cessed using the GCOS software and scanned using the
Aﬀymetrix Scanner. Expression analysis was performed
for all small RNAs for Homo sapiens (e.g., miRNA,
small nuclear RNAs like snoRNA and scaRNA) and sepa-
rately for Sanger miRNA registry content (miRBase 11.0,
http://microrna.sanger.ac.uk/) for Homo sapiens.
2.4. miRNA qRT-PCR. miRNA reverse transcription was
performed using the TaqMan microRNA Reverse transcrip-
tion Kit (Applied Biosystems) at 16◦C for 30 min, 42◦Cf o r
30min, and denaturation of the enzyme at 85◦C for 5min.
The RT reaction was performed at 37◦C for 1 hour followed
by 5min at 95◦C. TaqMan microRNA assays (Applied
Biosystems) were performed using the 7500 Fast Real-Time
PCR System at the 9600 emulation run mode. Ct values
were converted into copy numbers (copy no. = 2(−Ct))a n d
normalized to RNU44.
2.5. Statistical Analysis. Statistical analyses were performed
using GraphPad Prism software. Values are expressed asCardiology Research and Practice 3
means ± SEM. Unpaired Student’s t-tests were used to
compare data. A P value <.05 (two sided) was considered
signiﬁcant.Foranalysisofmicroarrayexpressiondata,atwo-
sample t- t e s tw a sc a r r i e do u tf o re v e r yg e n e ,f o l l o w e db y
multiplicity correction to control the false discovery rate
(FDR) at .05.
3. Results
We initially performed expression proﬁling of all small RNAs
(1770 genes, Figure 1) in the whole blood samples. Three
miRNAs passed the FDR cutoﬀ of 0.05: miR-584 (7.9-fold
higher in healthy versus CAD patients, P = .000103, t-
test), miR-542-5p (3.9-fold higher in healthy versus CAD
pts, P = .000168, t-test), and miR-187∗ (2.77-fold higher
in healthy versus CAD pts, P = 8.1 × 10−5, t-test). However,
signal intensities for miR-542-5p and miR-187∗ were very
low and not detected in most samples. Separately, we
performed an analysis of Sanger registry miRNAs (848 for
Homo sapiens) in the whole blood samples, but none of
the miRNAs passed the FDR cutoﬀ of 0.05. Ten miRNAs
passed a FDR cutoﬀ of 0.10, but only one (miR-129-5p,
1.57 fold higher in healthy patients, P = .000044) of
these miRNAs had consistently detectable signal across
the 10 blood samples. miR-584 was not among these 10
miRNAs. Although we were able to detect some diﬀerences
in whole blood miRNA levels between healthy subjects and
CAD patients (miR-584, in particular), our microarray data
suggest that, similar to other reports [14], levels of miRNAs
in the blood are low and microarrays may lack the sensitivity
to adequately identify miRNAs that might serve as vascular
disease biomarkers. Interestingly, among the miRNAs that
tended to show consistent diﬀerences between healthy and
CAD blood, miRNA expression was generally higher in the
blood of healthy subjects, a ﬁnding previously observed by
others [8].
Next, we performed qRT-PCR on RNA isolated from
whole blood of another 10 patients with angiographically
signiﬁcant CAD and 15 healthy subjects. We evaluated the
levels of miRNAs that, based on our microarray data, were
highly expressed in blood and tended to have diﬀerent levels
of expression between the two groups. This analysis included
miR-150, miR-584, miR-21, miR-24, miR-126, miR-92a,
miR-34a, miR-19a, miR-145, miR-155, miR-222, miR-378,
miR-29a, miR-30e-5p, miR-342, and miR-181d. Among
these we found that miR-19a, miR-584, miR-155, miR-222,
miR-145, miR-29a, miR-378, miR-342, miR-181d, miR-150,
and miR-30e-5p were signiﬁcantly downregulated in the
blood of patients with CAD compared to healthy subjects
(Figure 2). Furthermore, we also assessed expression of these
11 miRNAs in a cohort of patients who had ≥2r i s kf a c t o r s
for CAD, but did not have angiographically signiﬁcant CAD.
We found that there was no diﬀerence in whole blood
miRNA expression of this latter group compared to that in
patients with signiﬁcant CAD (not shown), suggesting that
these miRNAs are markers for vascular inﬂammation rather
than markers speciﬁc for signiﬁcant CAD.
There has been one report that miRNA expression in
blood may be inﬂuenced by medications [8]. Indeed, one
m
i
R
-
1
9
a
m
i
R
-
5
8
4
m
i
R
-
1
5
5
m
i
R
-
2
2
2
m
i
R
-
1
4
5
m
i
R
-
2
9
a
m
i
R
-
3
7
8
m
i
R
-
3
4
2
m
i
R
-
1
8
1
d
m
i
R
-
3
0
e
-
5
p
m
i
r
-
1
5
0 0
0.2
0.4
0.6
0.8
1
R
a
t
i
o
o
f
C
A
D
t
o
h
e
a
l
t
h
y Healthy
Figure 2: Identiﬁcation of miRNAs that are decreased in CAD
patients compared to healthy subjects. TaqMan miRNA assays were
performed on RNA isolated from blood obtained from 2 diﬀerent
groups: patients with angiographically signiﬁcant CAD (n = 15)
and healthy volunteers (n = 5). P values: miR-19a = .012, miR-584
= .036, miR-155 = .002, miR-222 = .001, miR-145 = .008, miR-29a
= .012, miR-378 = .001, miR-342 = .001, miR-30e-5p = .02, and
miR-150 = .006.
of the miRNAs that we found to be downregulated in the
blood of patients with CAD is miR-155, which is known
to target the AT1 receptor [15]. Therefore, we assessed the
impact of medications on expression of miR-155, miR-145,
miR-181d, miR-222, miR-19a, miR-342, miR-29a, miR-30e-
5p, and miR-378. We compared the miRNA expression levels
in the blood of patients with angiographically signiﬁcant
CAD or ≥2 risk factors for CAD but not on ACEI or ARB
to that in blood of similar patients who were taking at least
one of medications. Interestingly, levels of miR-155, miR-
19a, miR-145, miR-222, miR-342, miR-30e-5p, and miR-378
(Figure 3) were signiﬁcantly decreased in patients taking
ACEI or ARB compared to those who were not, suggesting
that these medications may directly modulate expression of
these miRNAs, or they may inﬂuence inﬂammatory factors
that otherwise regulate their expression. Importantly, we did
not ﬁnd that statin use had a signiﬁcant eﬀect on the levels of
miRNAs identiﬁed in this study (not shown).
4. Discussion
Several recent studies have indicated that there is a potential
role for circulating miRNA levels as valuable biomarkers for
diﬀerent disease processes, including cancer, cardiomyopa-
thy,andacutemyocardialinfarction.Inthisstudy,wewanted
to address the hypothesis that miRNA expression levels in
blood could predict the presence of signiﬁcant coronary
artery disease in human subjects. We identiﬁed 11 miRNAs
whoseexpressionwassigniﬁcantlydownregulatedinpatients
with angiographic evidence of signiﬁcant atherosclerosis
compared to healthy subjects that were matched for age
and gender. In addition, our data suggest that inhibition of
the renin angiotensin system by ACEI or ARB use further
inﬂuences miRNA expression in blood. This study conﬁrms
previous reports showing diﬀerences in circulating miRNA
levels of patients with CAD compared to those of healthy
subjects [8, 16]. Our study diﬀers from the other studies in4 Cardiology Research and Practice
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Figure 3: Medications inﬂuence the circulating levels of speciﬁc
miRNAs. Expression data obtained from the patients (angiograph-
ically signiﬁcant CAD or ≥2 CAD risk factors but no signiﬁcant
CAD lesions) on ACEI or ARB compared to similar patients not
on ACEI or ARB. Circulating levels of miR-155, miR-19a, miR-
378, miR-222, miR-342, miR-145, and miR-30e-5p were decreased
in patients who were taking these medications. P values: miR-155
= .0007, miR-19a = .035, miR-29a = NS, miR-30e-5p = .011, miR-
145 = .003, miR-181d = NS, miR-222 = .002, miR-342 = .0036, and
miR-378 = .0004.
thecontentofthegroupofmiRNAsthatweredownregulated
in patients with CAD.
We performed this analysis using the PAXgene Blood
RNA system because it provides a way to stabilize RNA im-
mediately after sample collection and facilitates storage of
the samples for a relatively long period of time without
compromising RNA integrity [17, 18]. Importantly, mRNA
proﬁling of whole blood or peripheral mononuclear cells has
been previously applied to cardiovascular disease [19, 20],
and a relationship has been identiﬁed between mRNA levels
in whole blood and extent of coronary artery disease. Our
study extends this work by providing insight into the whole
blood expression of miRNAs that are potentially involved in
regulating these CAD genes.
In our qRT-PCR analysis of whole blood samples from
CAD patients, we found similar changes in expression of
miR-155 and miR-145 as what has been reported previously
[8]. However, we failed to detect changes in other miRNAs
that were described in this previous report, namely miR-
126 and miR-92a. There are several possible explanations
for this. First, we studied whole blood samples, whereas
plasma was studied previously. Thus our miRNA proﬁle
likely reﬂects intracellular and extracellular miRNAs levels in
contrast to exclusively extracellular miRNAs that would be
detected in plasma. Another diﬀerence in our study is that
we normalized miRNA expression to expression of RNU44,
a small nucleolar RNA that, based on our microarray
analysis, we found to be highly and consistently expressed
across blood samples from CAD patients and controls.
This study conﬁrmed the observation made by others
regardingthediﬃcultyofusingmicroarrayanalysistoproﬁle
miRNA expression in blood samples [14]. Undoubtedly,
this is in part due to the limitation of a relatively small
sample size for our microarray analysis, as well as reduced
sensitivity of the microarray method compared to qRT-
PCR. In addition, principal component analysis of our data
suggested that two of the miRNA proﬁles for healthy subjects
were actually similar to that of the CAD patients, suggesting
that these individuals may in fact have subclinical vascular
inﬂammation. This ﬁnding is in the process of being further
investigated. Despite this, we believe that careful selection
of patients and well-matched control subjects from a larger
group of well-characterized individuals reduced some of the
variability in our qRT-PCR analysis.
We can only speculate as to why expression of circulated
miRNAs is generally decreased in patients with CAD. It has
been hypothesized that levels of circulating miRNAs are
decreased in vascular disease because they have been taken
up into atherosclerotic lesions [8]. The levels of circulating
miRNAs may be aﬀected by multiple factors, including
transcription, processing and stability of the miRNAs within
circulating cells, as well as the ability of these cells to
release miRNAs into the plasma. Circulating miRNAs may
be delivered to cells in the heart or blood vessels through
microvesicles, exosomes, or apoptotic bodies [21]. Because
our study assessed miRNA expression in whole blood, our
ﬁndings are likely more reﬂective of changes in miRNA tran-
scription or processing rather than release from the circulat-
ing cells.
It remains to be determined whether downregulation of
miRNAs in CAD patients is directly involved in inﬂamma-
tion or a compensatory response to this process. Based on
our observed changes in miRNA expression in response to
ACEI/ARB therapy, we believe that circulating miRNA levels
reﬂect a compensatory response to inﬂammation. Further
experimental studies are necessary to explore the mechan-
isms by which CAD and therapies aﬀect tissue versus circu-
lating miRNA levels.
In summary, the present study provides insight into
whole blood levels of miRNAs in patients with CAD com-
pared to healthy subjects and demonstrates their potential
utility as biomarkers for vascular disease. Validation of
the changes in miRNA expression observed here in larger
studies will be a necessary step to conﬁrm their candidacy as
biomarkers and therapeutic targets. We believe that further
elucidation of the role that these miRNAs play in the
pathogenesisandprogressionofchronicCADwillcontribute
to our understanding of the disease process and lead to new
therapeutic and preventative strategies.
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